Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xianqing Deng has a total of 100 co-authors. Here are the top co-authors by number of shared publications:

  • Mingxia Song

    Affiliated Hospital of Jinggangshan University, Key Laboratory for Personalized Drug Therapy in Neuropsychiatric Disorders of Jiangxi Provincial Department of Education, Jiangxi Province Key Laboratory of Organ Development and Epigenetics, Clinical Medical Research Center, College of Traditional Chinese Medicine and Pharmacy, Jinggangshan University, Ji'an 343009, China

    8 shared publications
  • Ming-Xia Song

    Affiliated Hospital of Jinggangshan University, Jiangxi Province Key Laboratory of Organ Development and Epigenetics, College of Traditional Chinese Medicine and Pharmacy, Jinggangshan University, Ji’an, People’s Republic of China

    7 shared publications
  • Mingxia Song

    Affiliated Hospital of Jinggangshan University, Jiangxi Province Key Laboratory of Organ Development and Epigenetics, College of Traditional Chinese Medicine and Pharmacy, Jinggangshan University

    5 shared publications
  • Ying Zheng

    Affiliated Hospital of Jinggangshan University, Key Laboratory for Personalized Drug Therapy in Neuropsychiatric Disorders of Jiangxi Provincial Department of Education, Jiangxi Province Key Laboratory of Organ Development and Epigenetics, Clinical Medical Research Center College of Traditional Chinese Medicine and Pharmacy, Jinggangshan University Ji'an China

    5 shared publications
  • Guowen He

    Affiliated Hospital of Jinggangshan University, Key Laboratory for Personalized Drug Therapy in Neuropsychiatric Disorders of Jiangxi Provincial Department of Education, Jiangxi Province Key Laboratory of Organ Development and Epigenetics, Clinical Medical Research Center College of Traditional Chinese Medicine and Pharmacy, Jinggangshan University Ji'an China

    3 shared publications
  • Rui Yan

    Medical College, Jinggangshan University, Ji'an, Jiangxi, China

    3 shared publications

Latest Publications

  • Design, Synthesis, and Pharmacological Evaluation of Sulfur‐Containing Pitolisant Analogs as Potent H 3 R Antagonists for Epilepsy Therapy

    by Ying Zheng, Guowen He, Wei Xia, Jiuhong Kang, Xiang Ji, Ruokun Wu, Hao Qu, Mingxia Song, Xianqing Deng

    Although multiple antiseizure drugs (ASDs) are clinically accessible, epilepsy remains a debilitating neurological disorder with a high unmet need for more effective and better‐tolerated therapies. Antagonism of the histamine H 3 receptor (H 3 R) represents a promising alternative strategy, exemplified by the clinically approved inverse agonist/antagonist pitolisant (PIT) for narcolepsy. Herein, we designed a novel series of non‐imidazole H 3 R antagonists by introducing a sulfur atom into the PIT scaffold to modulate lipophilicity, flexibility, and target binding. The synthesis and pharmacological evaluation of 12 target compounds ( 3a–3h , 5a–5d ) are reported. Compounds 3e and 3f showed potent H 3 R antagonism with IC 50 values of 0.18 µM and 0.036 µM, respectively, with the latter more active than PIT (IC 50 = 0.1 µM). In the maximal electroshock (MES) model, 3f exhibited superior antiseizure activity (ED 50 = 14.0 mg/kg) compared to PIT (ED 50 = 16.3 mg/kg). What's more, compounds 3e and 3f showed significant seizure protection in a zebrafish pentylenetetrazol (PTZ) model, and favorable cytotoxicity and neurotoxicity profiles in cell and animal experiments. Compound 3f exhibits low hERG toxicity risk with an IC 50 of 1.83 µM compared to PIT (IC 50 = 1.51 µM), and excellent blood‐brain barrier penetration with a brain‐to‐plasma ratio of 4.56. Molecular docking studies revealed stable interactions with key H 3 R residues, including ASP114, VAL95, and PHE189. Collectively, these results indicate that 3f shows considerable promise as a lead candidate in the search for new antiepileptic drugs.

  • Design, synthesis and pharmacological evaluation of novel 2-aryloxazole-based H3 receptor antagonists as potent, antiseizure agents

    by Ying Zheng, Guowen He, Yingna Zhu, Hao Qu, Jieya Shang, Jianglong Wu, Zhaozhe Wang, Xianqing Deng

    This study aimed to develop novel non-imidazole histamine H3 receptor (H3R) antagonists as potential antiseizure agents. We designed and synthesized a series of 2-aryloxazole derivatives (4a-4t) by relocating a phenyl group from the piperidine side chain to the oxazole core of a previous the lead compound (5 g), aiming to optimize lipophilicity and receptor binding. Among the synthesized compounds, 4f exhibited the most potent H3R antagonistic activity (IC50 = 0.056 µM), superior to lead compound 5 g and the reference drug Pitolisant (PIT). Compound 4f also demonstrated high selectivity over other histamine receptor subtypes (H1R, H2R, and H4R). In vivo, 4f showed significant and sustained antiseizure efficacy in the maximal electroshock (MES) model in mice (ED50 = 17.36 mg/kg) and potently suppressed seizures in a zebrafish pentylenetetrazol (PTZ) model. Pharmacokinetic studies revealed favorable oral bioavailability (81.12%) and effective brain penetration (90 min brain-to-plasma (B/P) ratio = 4.15) with progressive accumulation. Preliminary safety profiling indicated minimal neurotoxicity at therapeutic doses and a lower hERG channel inhibition risk compared to PIT. These results identify 4f as a potent, selective, and brain-penetrable H3R antagonist with robust antiseizure activity and a favorable preclinical profile, supporting its further development as a novel antiseizure agent.


  • A dual-targeting antimicrobial agent: Discovery and mechanism of action of a novel 7H-Pyrrolo[3,2-f]quinazoline-1,3-diamine compound

    by Weiqing He, Yajing Tian, Ke Li, Jinman Che, Muchun Cheng, Jieya Shang, Yi Hua, Qiang Fu, Kunhao Qin, Yuanying Jiang, et al.

  • Retracted
    Open Access

    Recent progress in the exploitation of anti-cancer small molecules targeting angiogenesis

    by Ying Zheng, Hao Qiu, Ke Zhang, Xiang Ji, Mingxia Song, Xianqing Deng

    Angiogenesis is pivotal for cancer growth and metastasis, as tumours rely on new blood vessels to progress and spread. Antiangiogenic drugs represent a crucial therapeutic strategy that combats cancer by both obstructing the development of new blood vessels and disrupting existing tumour-associated vasculature. Recently, significant advancements have been made in antiangiogenic cancer therapies, as evidenced by the extensive literature covered in this review. Numerous novel angiogenesis inhibitors have been reported to exhibit significant efficacy: they not only suppress cancer metastasis and angiogenesis but also induce cancer cell apoptosis via multiple distinct mechanisms. This review comprehensively updates (2014-2025) small molecule angiogenesis inhibitors' design and structure-activity relationship (SAR), integrating latest developments. By systematically analysing the mechanisms of action and distinctive characteristics of these compounds, we aim to offer valuable insights and references to guide the ongoing development of next-generation anti-cancer agents targeting angiogenesis.


  • Synthesis of nonimidazole H3 receptor antagonists containing oxazole moiety and their antiseizure activity

    by Mengyu Deng, Ying Zheng, Jiawei Li, Ping Liu, Jiayi Jiang, Xinxin Long, Mingxia Song, Siming Liu, Xianqing Deng


  • Open Access

    Design, Synthesis, and Antimicrobial Activity Evaluation of Ciprofloxacin—Indole Hybrids

    by Mingxia Song, Yi Hua, Yuxin Liu, Xunli Xiao, Haihong Yu, Xianqing Deng

    With the overuse and misuse of antimicrobial drugs, antibacterial resistance is becoming a critical global health problem. New antibacterial agents are effective measures for overcoming the crisis of drug resistance. In this paper, a novel set of ciprofloxacin-indole/acetophenone hybrids was designed, synthesized, and structurally elucidated with the help of NMR and high-resolution mass spectrometry. The in vitro antibacterial activities of these hybrids against gram-positive and gram-negative pathogens, including four multidrug-resistant clinical isolates, were evaluated and compared with those of the parent drug ciprofloxacin (CIP). All the target compounds (MIC = 0.0625–32 μg/mL) exhibited excellent inhibitory activity against the strains tested. Among them, 3a (MIC = 0.25–8 μg/mL) showed comparable or slightly less potent activity than CIP. The most active hybrid, 8b (MIC = 0.0626–1 μg/mL), showed equal or higher activity than CIP. Moreover, compound 8b showed superior bactericidal capability to CIP, with undetectably low resistance frequencies. Furthermore, molecular docking studies conducted showed that 8b and CIP had a similar binding mode to DNA gyrase (Staphylocouccus aureus). Thus, hybrids 3a and 8b could act as a platform for further investigations.


  • Open Access

    Synthesis and anticancer properties of celastrol derivatives involved in the inhibition of VEGF

    by Mingxia Song, Jiantao Wen, Yi Hua, Yangnv Zhu, Qishan Xia, Qiaoyue Guo, Yiqin Luo, Xianqing Deng, Yushan Huang

    In this study, fourteen celastrol derivatives (1–14) were synthesised by esterification of celastrol at the 29th position. The in vitro anticancer activity of them was determined by the MTT assay. All the synthetic compounds showed significant antiproliferative activity against six cancer cells, with IC50 of the submicron molar level. The most promising compound (2) blocked the cell cycle in the G2 phase and inhibited the expression of VEGF and MMP-9 in gastric cancer cell line MGC-803. In flow cytometry analysis, compound 2 induced cancer cell apoptosis in a dose-dependent manner. In the mouse tumour xenograft model, compound 2 showed significant anti-tumour activity in vivo at the dosage of 2.5 mg/kg and 1 mg/kg, with a higher inhibition rate than 5-FU (10 mg/kg). What’s more, the anticancer mechanism involved in the inhibition of VEGF and the toxicity evaluation of compound 2 were also investigated.


  • Open Access

    Antiseizure Properties of Histamine H3 Receptor Antagonists Belonging 3,4-Dihydroquinolin-2(1H)-Ones

    by Yi Hua, Mingxia Song, Qiaoyue Guo, Yiqin Luo, Xianqing Deng, Yushan Huang

    H3R is becoming an attractive and promising target for epilepsy treatment as well as the discovery of antiepileptics. In this work, a series of 6-aminoalkoxy-3,4-dihydroquinolin-2(1H)-ones was prepared to screen their H3R antagonistic activities and antiseizure effects. The majority of the target compounds displayed a potent H3R antagonistic activity. Among them, compounds 2a, 2c, 2h, and 4a showed submicromolar H3R antagonistic activity with an IC50 of 0.52, 0.47, 0.12, and 0.37 μM, respectively. The maximal electroshock seizure (MES) model screened out three compounds (2h, 4a, and 4b) with antiseizure activity. Meanwhile, the pentylenetetrazole (PTZ)-induced seizure test gave a result that no compound can resist the seizures induced by PTZ. Additionally, the anti-MES action of compound 4a fully vanished when it was administrated combined with an H3R agonist (RAMH). These results showed that the antiseizure role of compound 4a might be achieved by antagonizing the H3R receptor. The molecular docking of 2h, 4a, and PIT with the H3R protein predicted their possible binding patterns and gave a presentation that 2h, 4a, and PIT had a similar binding model with H3R.


  • Open Access

    Design, Synthesis, and Pharmacology of New Triazole-Containing Quinolinones as CNS Active Agents

    by Wennan Zhao, Mingxia Song, Yi Hua, Yangnv Zhu, Wenli Liu, Qishan Xia, Xianqing Deng, Yushan Huang

    Epilepsy and major depressive disorder are the two of the most common central nervous system (CNS) diseases. Clinicians and patients call for new antidepressants, antiseizure medicines, and in particular drugs for depression and epilepsy comorbidities. In this work, a dozen new triazole-quinolinones were designed, synthesized, and investigated as CNS active agents. All compounds reduced the immobility time significantly during the forced swim test (FST) in mice at the dosage of 50 mg/kg. Compounds 3f–3j gave superior performance over fluoxetine in the FST with more reductions of the immobility time. Compound 3g also reduced immobility time significantly in a tail suspension test (TST) at the dosage of 50 mg/kg, though its anti-immobility activity was inferior to that of fluoxetine. An open field test was carried out and it eliminated the false-positive possibility of 3g in the FST and TST, which complementarily supported the antidepressant activity of 3g. We also found that almost all compounds except 3k exhibited antiseizure activity in the maximal electroshock seizure (MES) model at 100 or 300 mg/kg. Compounds 3c, 3f, and 3g displayed the ED50 of 63.4, 78.9, and 84.9 mg/kg, and TD50 of 264.1, 253.5, and 439.9 mg/kg, respectively. ELISA assays proved that the mechanism for the antiseizure and antidepressant activities of compound 3g was via affecting the concentration of GABA in mice brain. The molecular docking study showed a good interaction between 3g and the amino acid residue of the GABAA receptor. Excellent drug-like properties and pharmacokinetic properties of compound 3a–l were also predicted by Discovery Studio. These findings provided a new skeleton to develop agents for the treatment of epilepsy and depression comorbidities.